HC Wainwright Reaffirms "Buy" Rating for MoonLake Immunother

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $100.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 116.54% from the […]

Related Keywords

Switzerland , Stifel Nicolaus , Kristian Reich , Silva Jorge Santos , Moonlake Immunotherapeutics , Goldman Sachs Group , Wolfe Research , Moonlake Immunotherapeutics Company Profile , Nasdaq , Needham Company , Citadel Advisors , Pricet Rowe Associates Inc , Securities Exchange Commission , Avoro Capital Advisors , Get Free Report , Exchange Commission , Capital Advisors , Adage Capital Partners , Capital Partners , Nasdaq Mltx , Mltx , Medical , Reiterated Rating , Hc Wainwright ,